Overview

Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to investigate the bioequivalence of Mylan's alprazolam 1 mg Extended-release tablets to Pharmacia & Upjohn's Xanax XR 1 mg tablets following a single, oral 3 mg (3 x 1 mg) dose administered under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Mylan Pharmaceuticals
Treatments:
Alprazolam